Several antibodies targeting PD-1 or PD-L1 have received clinical approval as first- and second-line treatments for different malignancies and numerous clinical trials are ongoing to test the efficacy of these drugs when used alone or in combination with conventional anti-cancer drugs, as well as targeted therapies [128]. This evidence concerns the gene CD274 and cancer.